Faculty

Jennifer Nahum headshot

Jennifer L Nahum

CPNP-AC DNP PNP-BC RN

Clinical Assistant Professor

1 212 998 5300

433 First Avenue
New York, NY 10010
United States

expand all

collapse all

Professional overview

Dr. Jennifer Nahum is a Pediatric Nurse Practitioner (PNP) with experience as an emergency department nurse practitioner, as well as interest in neonatology. She spent her early nursing years in a bedside nurse in a Level III intensive care nursery in Philadelphia and currently practices in a busy emergency department in the Bronx. Dr. Nahum’s doctoral capstone project evaluated the use of a self-assessment tool via tablet computers to assess lymphedema symptoms in post-surgical breast cancer patients. This capstone sparked an interest in policy and she has since joined a task force to advocate for the Lymphedema Treatment Act (S 2373/HR 1608), which is currently under review by Congress.

Education

DNP, New York University;
MSN, University of Pennsylvania;
BSN, University of Pennsylvania

Honors and awards

NYU DNP Valedictorian; (2016)
NYU DNP Distinguished Student; (2016)
Dean's List, New York University; (2015)
Mayoral Proclamation; (2009)
Citation from Philadelphia City Council; (2009)
Claire Fagan Award (2007)

Specialties

Pediatric
Acute care
Emergency medicine

Professional membership

National Association of Pediatric Nurse Practitioners;
American Nurses Association

Publications

Publications

Does bioelectrical impedance analysis provide a reliable diagnosis of secondary lymphedema in breast cancer patients?

Nahum, J. L., & Squires, A. (2014). Journal of Clinical Outcomes Management, 21(2), 55-58.

Use of HbA1c in the diagnosis of diabetes in adolescents

Nahum, J. L., & Squires, A. (2014). Journal of Clinical Outcomes Management, 21(7), 298-299.
Abstract
Objective. To examine the screening practices of family practitioners (FPs) and pediatricians for type 2 diabetes (T2D) in adolescents. Design. Cross-sectional study. Setting and participants. The researchers randomly sampled 700 pediatricians and 700 FPs who participated in direct patient care using the American Medical Association Physician Masterfile using a mail survey. Exclusion criteria included providers who were residents, hospital staff, retirees, or employed by federally owned medical facilities, certified with a subspecialty, or over age 70. Main outcome measures. Providers were given a hypothetical case of an obese, female, teenaged patient with concurrent associated risk factors for T2D (family history of T2D, minority race, signs of insulin resistance) and asked what initial screening tests they would order. Respondents were then informed of the updated American Diabetes Association (ADA) guidelines that added hemoglobin A1c as a screening test to diagnose diabetes. The survey then asked if knowing this change in recommendation has changed or will change their screening practices in adolescents. Main results. 1400 surveys were mailed. After 2 were excluded due to mailing issues, 52% of providers provided responses. Of these, 129 providers reported that they did not care for adolescents (age 10-17), resulting in 604 providers in the final sample, 398 pediatricians and 335 FPs. The vast majority (92%) said they would screen the hypothetical case for diabetes, with most initially ordering a fasting test (fasting plasma glucose or 2-hour glucose tolerance test) (63%) or A1c test (58%). Of the 58% who planned to order HbA1c, only 35% ordered it in combination with a fasting test. HbA1c was significantly more likely to be ordered by pediatricians than by FPs (P = 0.001). After being presented with the new guidelines, 84% said then would now order HbA1c, a 27% increase. Conclusion. In response to information about the new guidelines, providers were more likely to order A1c as part of initial testing. Due to the lower test performance in children and increased cost of the test, the use of HbA1c without fasting tests may result in missed diagnosis of T2D in adolescents as well as increased health care costs.